Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | his description is incorporated by reference into Item 5.02 of this Current Report on Form 8-K. The above and the incorp |
| 28.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | his description is incorporated by reference into Item 5.02 of this Current Report on Form 8-K. The above and the incorp |
| 22.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3.01 above is incorporated by reference into this Item 5.02. Mr. Nielsen’s resignation was for personal reasons and is n |
Stammdaten
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Aligos Therapeutics, Inc. |
|---|---|
| Ticker | ALGS |
| CIK | 0001799448 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 37,7 Mio. USD |
| Beta | 2,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,186,000 | -24,193,000 | -2.45 | 88,533,000 | 53,545,000 |
| 2025-09-30 | 10-Q | 741,000 | -31,537,000 | -3.04 | 109,764,000 | 71,833,000 |
| 2025-06-30 | 10-Q | 965,000 | -15,863,000 | -1.53 | 134,706,000 | 101,866,000 |
| 2025-03-31 | 10-Q | 311,000 | 43,088,000 | -2.11 | 150,699,000 | 116,445,000 |
| 2024-12-31 | 10-K | 3,611,000 | -131,211,000 | -20.94 | 70,094,000 | -28,973,000 |
| 2024-09-30 | 10-Q | 1,250,000 | -19,259,000 | -3.07 | 88,426,000 | 50,096,000 |
| 2024-06-30 | 10-Q | 1,061,000 | 5,061,000 | 0.81 | 108,811,000 | 67,229,000 |
| 2024-03-31 | 10-Q | 694,000 | -34,863,000 | -5.58 | 127,902,000 | 59,796,000 |
| 2023-12-31 | 10-K | 6,191,000 | -87,679,000 | -34.20 | 151,527,000 | 92,080,000 |
| 2023-09-30 | 10-Q | 1,085,000 | -18,041,000 | -10.37 | 85,852,000 | 54,821,000 |
| 2023-06-30 | 10-Q | 4,294,000 | -18,791,000 | -0.43 | 106,130,000 | 69,635,000 |
| 2023-03-31 | 10-Q | 140,000 | -22,955,000 | -0.53 | 121,738,000 | 84,750,000 |
| 2022-12-31 | 10-K | 0 | -96,046,000 | -2.25 | 146,693,000 | 103,900,000 |
| 2022-09-30 | 10-Q | 0 | -18,621,000 | -0.44 | 164,069,000 | 122,013,000 |
| 2022-06-30 | 10-Q | 0 | -19,924,000 | -0.47 | 182,523,000 | 136,981,000 |
| 2022-03-31 | 10-Q | -35,615,000 | -0.84 | 210,470,000 | 152,886,000 | |
| 2021-12-31 | 10-K | 0 | -128,332,000 | 235,369,000 | 184,731,000 | |
| 2021-09-30 | 10-Q | -33,124,000 | -0.78 | 263,068,000 | 217,011,000 | |
| 2021-06-30 | 10-Q | -29,818,000 | 211,876,000 | 168,882,000 | ||
| 2021-03-31 | 10-Q | -27,674,000 | 234,540,000 | 195,220,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.